About this paper
Margins for pharmaceutical products – which had already been dropping in the last decade – are being driven down even further by international reference pricing, the practice of using the price of a product in other countries to set or negotiate the reimbursable price of a product in a given country. For pharmaceutical companies, a misstep in setting prices or choosing the launch sequence can be costly, both during the critical launch period and in market.
The SAS® solution for launch revenue optimization enables global pricing teams to proactively simulate and optimize launch timing and pricing decisions based on the predicted effect on global revenue – while accounting for the complex web of international reference pricing and country-specific rules.
SAS is the leader in analytics. Through innovative software and services, SAS empowers and inspires customers around the world to transform data into intelligence. SAS gives you THE POWER TO KNOW®.